PRGF-ENDORET® Infiltrations in the Treatment of Low Back Pain.

NCT ID: NCT06715085

Last Updated: 2025-02-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-23

Study Completion Date

2027-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the efficacy of PRGF in reducing pain and improving patients' quality of life. Researchers will compare an experimental drug (Plasma Rich in Growth Factors) to a control corticosteroid solution in saline solution.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diseases [C] - Musculoskeletal Diseases [C05

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: Plasma Rich in Growth Factors (PRGF)

The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.

Group Type EXPERIMENTAL

Plasma Rich in Growth Factors (PRGF)

Intervention Type DRUG

The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.

Control: Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.

The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.

Group Type ACTIVE_COMPARATOR

Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.

Intervention Type DRUG

The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma Rich in Growth Factors (PRGF)

The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.

Intervention Type DRUG

Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.

The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PRGF injection Corticosteroid solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of legal age (≥18 years).
* Patients diagnosed by Magnetic Resonance Imaging (MRI) with lumbar intervertebral disc degeneration(s) (Pfirrmann Scale \> 1).Patients with positive signs in MRI at L4-L5 and/or L5-S1 levels, including rupture of the annulus fibrosus, annular fissure, with or without disc herniation in its protrusion form will be included.
* Patients with low back pain with symptoms of low back pain for at least 3 months of evolution that has not responded to drug treatment.
* Numerical pain scale (COMI PAIN SCORE): between 6 and 10, average of the last month.
* Availability of an MRI performed in the last six months to allow the diagnosis.
* Availability of a complete blood test (hemogram, basic biochemistry and coagulation tests) performed in the last two months.
* Signed informed consent to participate in the clinical trial and authorization for data processing by the different centers involved for subsequent scientific publication.

Exclusion Criteria

* Patients with lumbar fracture, extruded herniated discs and herniated discs with signs of calcification are excluded.
* Patients with severe discopathies at levels adjacent to L4-L5 and/or L5-S1.
* Patients who have previously undergone spinal surgery.
* Patients who have undergone invasive procedures on the spine in the last 6 months, such as infiltrations, blocks, lavage or lumbar rhizolysis.
* Patients with neurogenic motor claudication.
* Patients with severe cardiovascular diseases, central nervous system diseases, epilepsy, coagulopathies, immunological diseases, infectious diseases (e.g. Hepatitis B and C, HIV, Syphilis), cancer or neurodegenerative pathologies.
* Patients with a history of drug use (e.g. alcoholism or others) and mental illness or marked psychological conditions related to pain.
* Morbidly obese patients (BMI \> 40 kg/m2).
* Women who are pregnant or breastfeeding or women of childbearing age who are not taking effective contraceptive measures as outlined in the Clinical Trials Facilitation and Coordination Group (CTFG) "Recommendations Regarding Contraception and Pregnancy Testing in Clinical Trials" V 1.1.
* Patients with pathologies that produce marked alterations in the efficacy of PRGF or coagulation, such as, for example: poorly controlled diabetes mellitus (glycosylated hemoglobin above 9%), hematological alterations (thrombopathy, thrombopenia, anemia with Hb \< 9), being subjected to immunosuppressive and/or dicoumarinic treatments, or any treatment with systemic corticosteroids during the 6 months prior to inclusion in the study
* Patients who present allergy to any component of the sedation or to the corticoid.
* Patients who have received previous back treatment with PRGF in the last 6 months.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotechnology Institute IMASD

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clínica Eduardo Anitua

Vitoria-Gasteiz, Alava, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aitana Sainz

Role: CONTACT

+34 653 31 75 17

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aitana Sainz

Role: primary

+35653317517

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BTIIMD-03-EC-23-DISC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intradiscal Platelet Rich Plasma
NCT04544709 TERMINATED PHASE4